VEGF-targeted therapy: mechanisms of anti-tumour activity.
about
PI3K/AKT/mTOR Pathway in AngiogenesisPredictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasetsVascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancerModes of resistance to anti-angiogenic therapyAxitinib for the management of metastatic renal cell carcinomaMyeloid-derived suppressor cells: linking inflammation and cancerContrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vesselsThe Foxc2 transcription factor regulates tumor angiogenesisHarnessing the immune system to improve cancer therapyAnticoagulation in combination with antiangiogenesis and chemotherapy for cancer patients: evidence and hypothesisEmerging molecular classifications and therapeutic implications for gastric cancerCombination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamicsRecent developments in receptor tyrosine kinases targeted anticancer therapyAntitumor effects of the benzophenanthridine alkaloid sanguinarine: Evidence and perspectivesVascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularizationThymidine Phosphorylase in Cancer; Enemy or Friend?Progress toward overcoming hypoxia-induced resistance to solid tumor therapyCritical evaluation of ramucirumab in the treatment of advanced gastric and gastroesophageal cancersTargeting angiogenesis in gynecologic cancersExploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunitiesBiosafe nanoscale pharmaceutical adjuvant materialsIs carbonic anhydrase IX a validated target for molecular imaging of cancer and hypoxia?Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalitiesAngiogenesis in metastatic colorectal cancer and the benefits of targeted therapyAnti-angiogenesis and metastasis: a tumour and stromal cell allianceImmune escape mechanisms in colorectal cancer pathogenesis and liver metastasisStrategies to target tumors using nanodelivery systems based on biodegradable polymers, aspects of intellectual property, and marketClinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancerTargeting the tumor vasculature to enhance T cell activitySolution structure of the major G-quadruplex formed in the human VEGF promoter in K+: insights into loop interactions of the parallel G-quadruplexesPotent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model.The biological complexity of colorectal cancer: insights into biomarkers for early detection and personalized careRelationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancerUnraveling the Anticancer Effect of Curcumin and ResveratrolMechanisms of resistance to anti-EGFR therapy in colorectal cancerTargeting the VEGF-C/VEGFR3 axis suppresses Slug-mediated cancer metastasis and stemness via inhibition of KRAS/YAP1 signalingLymphoma: immune evasion strategiesPathological bases for a robust application of cancer molecular classificationFGF receptors: cancer biology and therapeuticsAssessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: focus on the cancer hallmark of tumor angiogenesis
P2860
Q21129332-CA8A77CD-8971-4272-BCE0-BB6DD7CA879CQ21183974-60B81885-E2A0-4E30-B1D8-2BEB1F54A12AQ24202199-9BA01756-5197-497A-B866-30DB688B026CQ24608005-88F87D06-7B9A-4B69-B1F3-897450169EF6Q24613720-CE280A2F-5FF7-4972-9A30-C6DF07437F61Q24641811-F0FB40F7-95E4-496C-9C1A-D879087E2E97Q24644150-FBD123AA-4AB0-4034-8064-FE4CBCBE7BDBQ24647592-03393B3F-B1E2-49FB-B9B1-02C62F7BB2D5Q26738698-0B7DA044-5F51-4919-BD76-2D292CA95A8EQ26740812-9BB3BB87-AC0D-46B8-A108-A404F099C56CQ26745525-E97FE3CD-713A-4365-9641-BAB22560AE38Q26746067-D36D929C-5DEC-4F3C-B6B7-CBED39DC4AB5Q26751331-2FABFE18-CE06-4154-8A97-AC3100226EE2Q26769949-35A9C9D0-4B01-4196-AB67-057A878709ECQ26781833-41FDA2A7-AAEB-4B5C-8763-3580CE167FFEQ26795650-81E3ACAC-4497-429C-B918-26D1AE0D48D5Q26796405-61EF0E65-F0DE-4E98-9BA4-34749E5BA200Q26801289-2E645266-E1E9-473E-91EE-BA2DAC81FB67Q26824766-8BEBDBE0-360B-4E52-9358-3BCDD6A2276AQ26828930-747AA8CF-BA28-4A9E-8B99-73F5E9C76B92Q26829798-668A1FA8-6B14-4D8B-9685-6B22E139D84CQ26849504-163E4C74-64DF-4DA5-BA5C-2AF29A292E49Q26852437-14807B43-925B-4419-BFE9-789957C1FEEBQ26853604-EAC8EF17-D8A4-4FF2-9A83-F51C4C2F1B75Q26862741-7C718FAF-FC57-4F40-8A46-D65966E09F62Q27002388-614E00ED-554D-4B24-A946-2049DBF46C3AQ27015050-83C6AC0B-26DA-457C-B664-5A6965CB415CQ27024235-C55715BB-F813-4E17-B015-15BECFF3B4F8Q27026329-6E921096-5260-4513-A6C5-E762100F6188Q27679870-9F875FE0-4E13-4714-8D07-FFBB9FB773BAQ27853074-E7585B80-33E8-4D1F-A411-8DFEA510AD48Q28066460-6840A1FD-7285-403C-A9E5-A1F9821D6EC4Q28068654-C0ED9CAB-ED0A-475F-A9E1-DFADE5C199B4Q28073155-97DDC4AF-F0E8-4312-9AE5-5D7F6E9D5150Q28074073-5C5BDE62-05B3-4FA7-B657-7C9620E55D14Q28078716-F77165EC-9A0D-41F4-9BA3-65B880BB859DQ28080705-9B35C851-36DF-4A48-A456-B51811916C0DQ28082201-D01BC562-9690-4D21-BB71-7B1D6A00FBE5Q28291186-DB12D573-ADA6-4ECA-9704-7CB66271805AQ28397726-985AEA9C-51AC-423B-B1D3-8ED870533ED7
P2860
VEGF-targeted therapy: mechanisms of anti-tumour activity.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
VEGF-targeted therapy: mechanisms of anti-tumour activity.
@ast
VEGF-targeted therapy: mechanisms of anti-tumour activity.
@en
VEGF-targeted therapy: mechanisms of anti-tumour activity.
@nl
type
label
VEGF-targeted therapy: mechanisms of anti-tumour activity.
@ast
VEGF-targeted therapy: mechanisms of anti-tumour activity.
@en
VEGF-targeted therapy: mechanisms of anti-tumour activity.
@nl
prefLabel
VEGF-targeted therapy: mechanisms of anti-tumour activity.
@ast
VEGF-targeted therapy: mechanisms of anti-tumour activity.
@en
VEGF-targeted therapy: mechanisms of anti-tumour activity.
@nl
P356
P1476
VEGF-targeted therapy: mechanisms of anti-tumour activity.
@en
P2093
Daniel J Hicklin
Lee M Ellis
P2888
P304
P356
10.1038/NRC2403
P407
P577
2008-07-03T00:00:00Z
P5875
P6179
1020862106